• Explore /
  • Poster
  • / C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.

C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.

Abstract Poster

Authors

null

Yoshihiko Tomita

Niigata University Graduate School of Medicine, Niigata, Japan

Yoshihiko Tomita , Robert J. Motzer , Toni K. Choueiri , Brian I. Rini , Hirotsugu Uemura , Mototsugu Oya , Laurence Albiges , Yosuke Fujii , Yoshiko Umeyama , Bo Huang , Alessandra Di Pietro , Manuela Schmidinger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02684006

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 670)

DOI

10.1200/JCO.2023.41.6_suppl.670

Abstract #

670

Poster Bd #

H2

Abstract Disclosures

Similar Posters

First Author: Yoshihiko Tomita

First Author: Yoshihiko Tomita

First Author: Kevin Yan

Poster

2022 ASCO Genitourinary Cancers Symposium

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

First Author: Ajeet Gajra